Grifols SA
GRFS
View Detailed Chart
9.135USD
+0.115+1.27%
Market hours （ET）Quotes delayed by 15 min
2.35BMarket Cap
15.03P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.27%
5 Days
-0.05%
1 Month
+8.75%
6 Months
+4.16%
Year to Date
+22.78%
1 Year
+21.64%
View Detailed Chart
TradingKey Stock Score of Grifols SA
Currency: USD Updated: 2025-12-19Key Insights
Grifols SA's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 63/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.20.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Grifols SA's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
8
analysts
Buy
Current Rating
12.200
Target Price
+35.86%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Grifols SA Highlights
StrengthsRisks
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 22.33% year-on-year.
Undervalued
The company’s latest PE is 14.84, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 150.82M shares, decreasing 7.67% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 1.91K shares of this stock.
Grifols SA News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Grifols SA Info
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
Ticker SymbolGRFS
CompanyGrifols SA
CEOAbia (Jose Ignacio)
Websitehttps://www.grifols.com/
FAQs
What is the current price of Grifols SA (GRFS)?
The current price of Grifols SA (GRFS) is 9.135.
What is the symbol of Grifols SA?
The ticker symbol of Grifols SA is GRFS.
What is the 52-week high of Grifols SA?
The 52-week high of Grifols SA is 11.140.
What is the 52-week low of Grifols SA?
The 52-week low of Grifols SA is 6.190.
What is the market capitalization of Grifols SA?
The market capitalization of Grifols SA is 2.35B.
What is the net income of Grifols SA?
The net income of Grifols SA is 169.72M.
Is Grifols SA (GRFS) currently rated as Buy, Hold, or Sell?
According to analysts, Grifols SA (GRFS) has an overall rating of Buy, with a price target of 12.200.
What is the Earnings Per Share (EPS TTM) of Grifols SA (GRFS)?
The Earnings Per Share (EPS TTM) of Grifols SA (GRFS) is 0.608.
Related Instruments
-0.43%
+0.21%
+0.57%
+0.32%
+0.65%
+2.35%
+1.11%
-0.31%
-0.22%
+0.31%
-0.60%
+0.03%
+0.42%
-0.23%
-0.06%
+0.52%
+1.64%
0.00%
+0.52%
+2.08%Popular Symbols
